Purpura, Thrombocytopenic, Idiopathic
Conditions
Keywords
Purpura, Thrombocytopenic, Idiopathic, ITP, Immunoglobulin, Intravenous
Brief summary
The efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L, in patients with ITP will be assessed and compared with data obtained from literature.
Detailed description
Sanquin has developed, in cooperation with the Finnish Red Cross Blood Transfusion Service (FRCBTS), a liquid intravenous immunoglobulin product, IVIG-L. The liquid formulation of intravenous immunoglobulin simplifies infusion, eliminates possible mistakes in the reconstitution with water for injection and reduces space requirements in storage. In addition to donor selection and screening, several procedures have been included in the production process to improve viral safety. In this clinical trial, the efficacy and safety of IVIG-L in patients with ITP will be assessed and compared with data obtained from literature. IVIG-L will also be studied in patients with hypogammaglobulinemia.The results from both studies will be used for an application for marketing authorisation of IVIG-L in Finland and the Netherlands.
Interventions
DRUGIVIG-L
Sponsors
Prothya Biosolutions
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with chronic ITP with a platelet count of about 20x109/L and at high risk of bleeding * Patients with chronic ITP with a platelet count of about 20x109/L, who have to undergo surgery * A stable clinical situation (no activity of any other disease) * Age at least 18 yrs * The patient/legally acceptable representative has signed the consent form
Exclusion criteria
* The presence of another autoimmune disease related with thrombocytopenia such as systematic lupus erythematosus (SLE), rheumatoid arthritis (RA) or nephritis * Patients with drug-induced thrombocytopenia or immunologic thrombocytopenia of infectious origin (in particular, Hepatitis, Epstein-Barr virus, Toxoplasma, HIV) * Massive splenomegaly * Treatment with any other investigational drug within 7 days before study entry or previous enrolment in this study * Having an ongoing progressive terminal disease, including HIV infection * Known with allergic reactions against human plasma, plasma products or intravenous immunoglobulin * Presence of conditions predisposing for bleeding: anaemia (hemoglobin \< 5.5 mmol/L), renal or urogenital disease, malignant disease (with the exception of basalioma, cervix carcinoma in situ), history of intracranial or aortic aneurysm, stroke, oeso-gastro-intestinal disorders with a bleeding potential, severe hypertension (diastole \> 110 mm Hg). * Use of corticosteroids for an acute situation within 7 days before study entry. Patients using corticosteroids prophylactically can be included * Splenectomy in the previous two weeks * Renal insufficiency (plasma creatinine \> 115µmol/L) * Pregnancy or lactation * Known with insufficiency of coronary or cerebral circulation * IgA deficiency and anti-IgA antibodies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of IVIG-L | — |
| The safety of IVIG-L | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare data on efficacy and safety of IVIG-L with data obtained from literature | — |
Countries
Poland
Outcome results
None listed